Arcoxia drug etoricoxib

Arcoxia is a pharmaceutical drug made by Merck & Co. Arxocia is promoted as causing fewer side effects such as stomach disorders and complications than some older painkillers. COX-2 inhibitors were designed as a safer long-term alternative to NSAIDs but have been linked with an increased risk of heart attacks. Vioxx, an older COX-2 inhibitor also made by Merck, was pulled from the market in 2004 after research showed it doubled the risk of heart attack and stroke in people who took it for at least 18 months.

Arcoxia is COX-2 inhibitor
Arcoxia is a COX-2 inhibitor while diclofenac belongs to an older class of therapies known as non-steroidal anti-inflammatory drugs or NSAIDs, which includes aspirin and ibuprofen. "Our results indicate that the rate of clinically important upper gastrointestinal events was lower with the COX-2 selective inhibitor etoricoxib than it was with the traditional NSAID diclofenac," said Dr. Loren Laine of the University of Southern California Keck School of Medicine in Los Angeles. There were fewer ulcers in patients taking the new drug and more patients continued to take the treatment, she added. A study published in November 2006 found Arcoxia did not raise heart risks as compared to diclofenac, but Dr. Steve Nissen, an expert on such drugs at the Cleveland Clinic in Ohio, questioned whether it was useful to compare a new drug to diclofenac, which is known to cause many side-effects.

home - tongkat ali net

Additional links on this website
5-HTP supplements